Who is sponsoring NCT03068208?

NCT03068208 is sponsored by Chulalongkorn University.

What drugs are being tested in NCT03068208?

Interventions in NCT03068208: Methylene blue-mediated photodynamic therapy.

What condition does NCT03068208 study?

NCT03068208 studies Lichen Amyloidosis.

Is NCT03068208 still recruiting?

NCT03068208 is currently status unknown. Last updated 1 March 2017.

Last reviewed 2017-03-01 · How we verify

NCT03068208

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Status unknown NA Last updated 1 March 2017

What this trial tests

NA trial testing Methylene blue-mediated photodynamic therapy in Lichen Amyloidosis in 15 participants. Status unknown.

Timeline

1 May 2017

Primary endpoint
30 April 2018

30 June 2018

Quick facts

Lead sponsor	Chulalongkorn University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	15
Start date	1 May 2017
Primary completion	30 April 2018
Estimated completion	30 June 2018
Sites	1 location across Thailand

Drugs / interventions tested

Methylene blue-mediated photodynamic therapy

Conditions studied

Lichen Amyloidosis — all drugs for Lichen Amyloidosis →

Sponsor

Chulalongkorn University

Who can join

18 and older, any sex, with Lichen Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy of Methylene blue mediated Photodynamic therapy for primary localized cutaneous amyloidosis treatment in Asians, pilot study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Methylene blue-mediated photodynamic therapy

Trials testing the same drug.

NCT03098342 — Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer fo · NA · unknown

Other Chulalongkorn University trials

Trials by the same sponsor.

NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03068208 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
Last refreshed: 1 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03068208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing